Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes - Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00071422

Locations


United States, California
	Diabetes and Endocrine Associates
	La Jolla, California, United States, 92037
	Diablo Clinical Research
	Walnut Creek, California, United States, 94598
	VA Hospital UCSD
	San Diego, California, United States, 92161

United States, Colorado
	Longmont Medical Research Network
	Longmont, Colorado, United States, 80501

	Denver, Colorado, United States, 80209

United States, District of Columbia
	MedStar Clinical Research Center
	Washington, District of Columbia, United States, 20003

United States, Massachusetts
	Future Care Studies
	Springfield, Massachusetts, United States, 01107

United States, Montana
	Mercury Street Medical
	Butte, Montana, United States, 59701

United States, New York
	Diabetes-Endocrinology Center of WNY
	Buffalo, New York, United States, 14209

United States, North Carolina
	Piedmont Medical Group
	Winston Salem, North Carolina, United States, 27103
	UNC Diabetes Care Center
	Durham, North Carolina, United States, 27713

United States, Oregon
	Clinical Research Institute of Southern Oregon
	Medford, Oregon, United States, 97504

United States, South Carolina
	Mountain View Clinical Research
	Greer, South Carolina, United States, 29651

United States, Texas
	Dallas Diabetes and Endocrine Center
	Dallas, Texas, United States, 75230
	DGD Research Associates
	San Antonio, Texas, United States, 78229
	University of Texas Health Science Center - Texas Diabetes Institute
	San Antonio, Texas, United States, 78207

United States, Virginia
	Charlottesville Medical Research
	Charlottesville, Virginia, United States, 22911

Sponsors and Collaborators

Procter and Gamble